2023788-19-2Tirzepatide 2381089-83-2 Retatrutide BPC-157 137525-51-0 Cagrilintide

Tizepatide (product name: Zepbound) It is a dual agonist of glucose dependent insulinotropic polypeptide (GIP) receptor and glucagon like peptide-1 (GLP-1) receptor developed by Eli Lilly and Company. It can help patients with type 2 diabetes to achieve powerful blood sugar control and significant weight loss effect by simulating the natural action of human incretin.